TNF and rheumatoid arthritis: As a relatively new member of the TNFα inhibitor family, certolizumab pegol (CZP) was developed as a novel polyethylene glycolylated (PEG) Fc-free anti-TNFα agent [9,10] and is approved for the treatment of adults suffering from RA not responding to conventional therapy.